November 2015 Page 1
|
|
- Samson O’Connor’
- 7 years ago
- Views:
Transcription
1 SUMMACARE PHARMACY & THERAPEUTICS COMMITTEE MONOGRAPH November, 2015 PREPARED BY MEDIMPACT HEALTHCARE SYSTEMS, INC Rexulti (brexpiprazole) GENERIC BRAND STRENGTH DOSAGE FORM ROUTE GPID (GCN) EXCEPTION/OTHER brexpiprazole Rexulti 0.25, 0.5, 1, 2, 3 and 4 mg tablet oral 38278, 38476, 38589, 38609, 38618, MANUFACTURER Otsuka Pharmaceutical Co. FDA APPROVED INDICATION(S) Rexulti is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Treatment of schizophrenia DRUG CLASS BEHAVIORAL HEALTH OTHER; ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED PLACE IN THERAPY Rexulti is the newest addition to the second generation (atypical) antipsychotic class which currently contains Abilify (aripiprazole), Clozaril (clozapine), Fanapt (iloperidone), Geodon (ziprasidone), Invega (paliperidone), Latuda (lurasidone), Risperdal (risperidone), Saphris (asenapine), Seroquel (quetiapine) and Zyprexa (olanzapine). Of these agents, only Abilify, Clozaril, Zyprexa, Seroquel, Risperdal, and Geodon have generic therapeutic equivalents available. Rexulti is currently indicated for the treatment of schizophrenia and as an adjunct to antidepressants for the treatment of MDD. Currently, there are 2.4 million adults in the United States (U.S.) diagnosed with schizophrenia. Schizophrenia is a mental disorder in which patients lose touch with reality, unable to differentiate between what is real and what is not. Patients typically experience positive symptoms such as hallucinations and delusions, and some also experience negative symptoms such as loss in pleasure and the ability to engage in goal directed activities. Patients with schizophrenia can pose a danger to themselves and others. Therefore, it is important to manage their symptoms to mitigate potential harm. Antipsychotics are considered first line treatment for schizophrenia and have been shown to reduce the positive symptoms of hallucinations and delusions. Current practice deems all antipsychotics, with the exception of clozapine, equivalent in their efficacy for the treatment of schizophrenia. Clozapine has been shown to have a higher efficacy than other antipsychotics but due to its high side effect profile, clozapine is reserved only for refractory schizophrenia or those with suicidal ideation. Given the similar efficacies, the main determining factors in choosing an initial antipsychotic for schizophrenia are the side effect profile and the ease of administration. Although all antipsychotics are indicated for the treatment of schizophrenia, the evidence for its use in the treatment of Major Depressive Disorder (MDD) has grown in the last decade. Currently Abilify, Seroquel, and Zyprexa are FDA approved for augmenting antidepressants. MDD is a chronic and recurrent mood disorder that affects approximately 15 million people in the U.S. It is characterized by depressed mood or loss of interest in daily activities for at least a two week period. First line treatment for MDD is the use of an antidepressant such as a November 2015 Page 1
2 selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). However, despite treatment, most patients do not achieve adequate response or remission with antidepressants alone. Augmentation therapy with a second generation antipsychotic has been shown to increase remission rates and yield early treatment effects on core depressive symptoms. Rexulti may offer an alternate treatment option for patients that do not respond adequately or are intolerant to other antipsychotics. Similar to Abilify, Rexulti has a mild side effect profile, with the main adverse effects being weight gain and akathisia (the need for constant movement). Rexulti is taken once daily and is available only as an oral tablet. No trials have been conducted directly comparing Rexulti with other antipsychotics. There are ongoing clinical trials for Rexulti in the treatment of agitation associated with dementia due to Alzheimer s disease which may expand the treatment population eligible for Rexulti. EFFICACY The efficacy of Rexulti in the treatment of schizophrenia was assessed in two 6 week, randomized, double blind, placebo controlled, fixed dose trials in 1,076 patients meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision (DSM IV TR) criteria for schizophrenia. The first study (referred to as Study 3) consisted of 536 patients while the second study (Study 4) consisted of 540 patients. Patients in both studies were randomized in a 1:1:1 ratio to receive maintenance doses of either Rexulti 2 mg by mouth daily, Rexulti 4 mg daily or placebo. Patients in the Rexulti treatment groups were initiated on Rexulti 1 mg by mouth daily during days 1 to 4 and titrated to 2 mg daily on days 5 to 7. Patients in the 4 mg treatment group were then titrated up to 4 mg by mouth daily on day 8 and maintained at the 4 mg dose for the remaining 5 weeks of the trial. The primary efficacy outcome in both studies was the change in the Positive and Negative Syndrome Scale (PANSS) score at week 6 from baseline. PANSS is a 30 item scale that measures the positive and negative symptoms of schizophrenia as well as general psychopathology. PANSS scores range from 30 being the best to 210 being the worst. In both studies, patients on either dose of Rexulti had a greater decrease in PANSS score compared to placebo although the decrease in study 4 for the 2 mg dose of Rexulti was not statistically significant (see Table 1). Table 1. Summary of Efficacy Results for Studies in Schizophrenia (from Rexulti Prescribing Information) The efficacy of Rexulti in the treatment of MDD was assessed in two 6 week, double blind, placebo controlled, fixed dose trials in 980 patients meeting the DSM IV TR criteria for MDD (+/ anxiety symptoms) who had an inadequate response to prior antidepressant therapy (1 to 3 courses) and demonstrated an inadequate response throughout the 8 weeks of prospective antidepressant treatment before randomization. Study 1 consisted of 353 November 2015 Page 2
3 patients randomized in a 1:1 ratio to either receive Rexulti 2 mg by mouth daily or placebo with their current antidepressant therapy. Study 2 consisted of 627 patients randomized in a 1:1:1 ratio to either receive Rexulti 1 mg by mouth daily, Rexulti 3 mg daily or placebo with their current antidepressant therapy. Patients in the Rexulti treatment groups were initiated on Rexulti 0.5 mg by mouth daily for the first week, 1 mg by mouth daily for the second week and either maintained at 1 mg by mouth daily for the remainder of the 6 weeks or increased to either 2 or 3 mg by mouth daily during week 3 depending on their treatment arm. The primary outcome was the change in the Montgomery Asberg Depression Rating Scale (MADRS) score at week 6 from baseline. MADRS is a 10 item scale that assesses depressive symptomatology with 0 representing no symptoms and 60 representing the worst symptoms. Rexulti at all doses showed a greater decrease in MADRS score than placebo but only the 2 mg dose of Rexulti showed a statistically significant decrease (see Table 2). Table 2. Summary of Efficacy Results for Studies 1 and 2 for the Adjunctive Treatment of MDD (from Rexulti Prescribing Information) SAFETY Similar to other antipsychotics, Rexulti has a black box warning for increased risk of death in elderly patients with dementia related psychosis. Due to its additional indication for MDD, Rexulti also has a standard black box warning against antidepressants increasing the risk of suicidal thoughts and behaviors in patients of age 24 years and younger. In addition, Rexulti also has many warnings and precautions that are common among the antipsychotics. These include increased risk for: cerebrovascular adverse events in elderly patients with dementia, neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia, hyperlipidemia, weight gain, neutropenia, leukopenia, agranulocytosis, orthostatic hypotension, and seizures. Common adverse effects seen while using Rexulti for MDD (reported as absolute treatment effect) include akathisia (7%), weight gain (5%), somnolence (4.5%) and restlessness (3%). Adverse reactions lead to the discontinuation of treatment in 3% of Rexulti treated patients compared to 1% in the placebo group. For schizophrenia, the most common adverse effects associated with Rexulti (reported as absolute treatment effect) were weight gain (2%), tremor (2%), and akathisia (1%). Although Rexulti has not been studied in pregnancy, use of antipsychotics during the third trimester of pregnancy increases the risk for extrapyramidal and withdrawal symptoms in the newborn. In animal reproduction studies, November 2015 Page 3
4 no teratogenicity was observed with oral administration of Rexulti to pregnant rats and rabbits during organogenesis at doses up to 73 and 146 times, respectively, of maximum recommended human dose (MRHD) of 4 mg/day on a mg/m 2 basis. However, when pregnant rats were administered Rexulti during the period of organogenesis through lactation, the number of perinatal deaths of pups was increased at 73 times the MRHD. No lactation studies have been conducted with Rexulti but Rexulti is present in rat milk. Rexulti use has not been studied in pediatric and geriatric populations but based on a safety trial, the pharmacokinetics of Rexulti in elderly patients taking up to Rexulti 3 mg by mouth daily for 14 days were comparable to nonelderly populations. Dose adjustment of Rexulti is recommended in poor CYP2D6 metabolizers, patients with moderate to severe hepatic impairment (Child Pugh score 7) and patients with moderate, severe or end stage renal impairment (CrCl <60 ml/min). Rexulti is metabolized via CYP3A4 and CYP2D6. Therefore, dose reduction of Rexulti is recommended when used concomitantly with CYP3A4 and 2D6 inhibitors. However, no dose adjustment is required when using Rexulti with paroxetine and fluoxetine even though they are strong CYP2D6 inhibitors because their inhibition properties were already accounted for in the dosing recommendations. A dose increase of Rexulti is also recommended if used concomitantly with a CYP3A4 inducer. DOSAGE For schizophrenia, the recommended starting dose is 1 mg by mouth daily on days 1 to 4. Titrate to 2 mg daily on days 5 to 7 and then 4 mg daily on day 8 based on the patient s clinical response and tolerability. The maximum recommended daily dosage is 4 mg. For MDD, the recommended Rexulti starting dose is 0.5 to 1 mg by mouth daily. Titrate weekly to a target dose of 2 mg daily based on the patient s clinical response and tolerability. Rexulti can be taken with or without food. The patient should be reassessed periodically to determine appropriate dosage and continued need for treatment. In patients with moderate to severe hepatic impairment (Child Pugh score 7) or patients with moderate, severe or end stage renal impairment (CrCl <60 ml/min), the maximum recommended dose is 2 mg for MDD and 3 mg for schizophrenia. Dose adjustments as shown in Table 3 are also required in CYP2D6 poor metabolizers and patients taking CYP2D6 inhibitors or CYP3A4 inducers or inhibitors. Table 3. Dosage Adjustments of Rexulti for CYP2D6 Poor Metabolizers and for Concomitant Use with CYP3A4 and CYP2D6 Inhibitors and/or CYP3A4 Inducers (from Rexulti Prescribing Information) November 2015 Page 4
5 COST DRUG REGIMEN COST/UNIT COST PER 30 DAYS Rexulti (brexpiprazole) 0.25, 0.5, 1, 2, 3 and 4 mg oral tablets MDD: 2mg daily Schizophrenia: 4 mg daily AWP= $34.62 (all strengths) $1039 Abilify (aripiprazole) 2, 5, 10, 15, 20 and 30 mg oral tablets Seroquel XR (quetiapine) 150, 200, 300, 400 mg tablet Zyprexa (olanzapine) 5mg, 10mg, 20mg Risperdal (risperidone) 1, 2, 3, 4 mg tablet Geodon (ziprasidone) 20, 40, 60, 80 mg capsule Invega (paliperidone) 3, 6, 9 mg tablet MDD: 2 15mg daily Schizophrenia: mg daily MDD: mg daily Schizophrenia: mg daily MAC= $14.49 $435 to $660 (2, 5, 10, 15mg) MAC=$21.99 (20 & 30mg) AWP= $16.38 $27.78 $491 to $1,660 Schizophrenia:10 20mg daily MAC=$0 18 $0.45 $5 to $14 Treatment resistant depression:5 20mg daily Schizophrenia: 2 8mg daily MAC=$0.12 $0.25 $7 to $15 Schizophrenia: 20mg 80mg BID MAC=$1.68 $1.97 $101 to $118 Schizophrenia: 3 12mg daily AWP= $23.09 $33.99 $693 to $2039 FORMULARY PLACEMENT RECOMMENDATIONS Based on this initial assessment of available clinical and financial information, consider NOT ADDING Rexulti to the formulary pending complete review by the appropriate oversight committee for the plan. Commercial: Specialty with Step Therapy Trial of two atypical antipsychotics, SSRIs, or SNRIs and Quantity limit of 1 tablet daily HIEx: Specialty with Step Therapy Trial of two atypical antipsychotics, SSRIs, or SNRIs and Quantity limit of 1 tablet daily REFERENCES Rexulti [Prescribing Information]. Otsuka Pharmaceutical Co.: Tokyo, Japan July Otsuka Pharmaceutical Co. [Media Release]. U.S. FDA Approves Otsuka and Lundbeck s REXULTI (Brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia Available at: us.com/newsroom/pages/newsarticle.aspx?itemid=13 UpToDate, Inc. Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment. UpToDate [database online]. Waltham, MA. Available at: US National Institutes of Health. Brexpiprazole. Clinical Trials. Available at: National Guideline Clearinghouse. Practice guideline for the treatment of patients with major depressive disorder, third edition. Available at: Second generation Antipsychotics in the Treatment of Major Depressive Disorder. Expert Rev Neurother. 2013;13(7): Available at: November 2015 Page 5
ATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
More informationOverview of Mental Health Medication Trends
America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationBelow, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.
[Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM
More informationAnalysis of New Brand Name Drugs for MDD and Bipolar I Depression/Schizophrenia. By Minh Vo, DO
Analysis of New Brand Name Drugs for MDD and Bipolar I Depression/Schizophrenia By Minh Vo, DO Fetzima Brand: Fetzima Generic: levomilnacipran (generic not available) Commonly Prescribed for: major depressive
More informationState of Louisiana. Department of Health and Hospitals Bureau of Health Services Financing
Bobby Jindal GOVERNOR State of Louisiana Department of Health and Hospitals Bureau of Health Services Financing Kathy H. Kliebert SECRETARY The purpose of this memo is to advise you that effective September
More informationPage 1 of 73. Initial Recommended Maximum Dose Dose Dose. 30 mg. /day. /day. /day. 2 mg. Schizophrenia adults (2.1) 10 mg. /day. /day. /day.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY (aripiprazole)
More informationUnderstanding Antipsychotic Medications
Understanding Antipsychotic Medications NARSAD RESEARCH National Alliance for Research on Schizophrenia and Depression 60 Cutter Mill Road, Suite 404 Great Neck, NY 11021 516-829-0091 1-800-829-8289 516-487-6930
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More informationAdminister a quarter of usual dose Strong CYP2D6 or CYP3A4 inhibitors Administer half of usual dose Strong CYP2D6 and CYP3A4 inhibitors
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY ABILIFY (aripiprazole)
More informationI. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,
More informationChapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects
More informationPsychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationUpdate on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
More information3 DOSAGE FORMS AND STRENGTHS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,
More informationChronic mental illness in LTCF. Chronic mental illness. Other psychiatric disorders.
Chronic mental illness in LTCF Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Chronic mental illness 1. Schizophrenia and Schizoaffective disorder. 2. Bipolar disorder (Type 1 and
More informationo DOSAGE AND ADMINISTRATION Dosage in Special Populations: The recommended initial dose is 0.5 mg BID in patients who are elderly
Some critics of Janssen, including plaintiff s lawyers, have stated it is improper for Risperdal to have been used to treat elderly dementia patients. As you consider that position, we suggest you consider
More informationDepression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
More informationThe following is a sample of psychotropic drug warnings that drug regulatory agencies
Chronology of International Drug Regulatory Agency Warnings about Psychotropic Drugs The following is a sample of psychotropic drug warnings that drug regulatory agencies around the world have issued.
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationMedication Guide LATUDA (luh-too-duh) (lurasidone hydrochloride) Tablets
Medication Guide LATUDA (luh-too-duh) (lurasidone hydrochloride) Tablets What is the most important information I should know about LATUDA? LATUDA may cause serious side effects, including: 1. Increased
More informationClinical Summary of Pediatric Metabolic AERS Reports. Judith Cope, MD, MPH Office of Pediatric Therapeutics/FDA
Clinical Summary of Pediatric Metabolic AERS Reports Judith Cope, MD, MPH Office of Pediatric Therapeutics/FDA 1 Clinical Summary of Pediatric Metabolic AERS Reports: Atypical Antipsychotics n=100 reports;
More informationWelcome to Who Wants to be an APNA Millionaire!
Welcome to Who Wants to be an APNA Millionaire! Drug-Drinks Interactions Drug-Drug Interactions Mary Gutierrez, PharmD, BCPP Clinical Professor of Pharmacy Practice (Psychiatry) Chapman University, School
More informationMedication Side Effects:
Medication Side Effects: Staying Healthy While on Psychotropic Medications Megan Maroney PharmD, BCPP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers the State University of New Jersey
More informationUsing Antipsychotics to Treat: Depression. Comparing Effectiveness, Safety, and Price
Using Antipsychotics to Treat: Depression Comparing Effectiveness, Safety, and Price Our Recommendations Although antipsychotics were developed to treat schizophrenia, newer ones are sometimes used to
More informationNew Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
More informationGUIDELINES FOR THE USE OF ATYPICAL ANTIPSYCHOTICS IN ADULTS. January 2012. 1 P a g e
GUIDELINES FOR THE USE OF ATYPICAL ANTIPSYCHOTICS IN ADULTS January 2012 1 P a g e First episode of psychosis or chronic psychosis First line: (equivalent choices, trial for 6 to 10 weeks) a) Risperidone
More informationSummary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline)
EMA/744222/2014 Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline) This is a summary of the risk management plan (RMP) for Rasagiline ratiopharm, which details the measures
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationASSESSMENT AND MANAGEMENT OF PSYCHOSIS IN PERSONS WITH DEMENTIA
ASSESSMENT AND MANAGEMENT OF PSYCHOSIS IN PERSONS WITH DEMENTIA Overview: Psychosis is a common clinical feature of dementia. Hallucinations and delusions are the two most common types of psychotic symptoms
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationReimbursement and Billing Guide
Reimbursement and Billing Guide Disclaimer This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage,
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationUltram (tramadol), Ultram ER (tramadol extended-release tablets); Conzip (tramadol extended-release capsules), Ultracet (tramadol / acetaminophen)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.35 Subject: Tramadol Acetaminophen Page: 1 of 8 Last Review Date: September 18, 2015 Tramadol Acetaminophen
More informationAntipsychotics and the Nursing Home
Antipsychotics and the Nursing Home Lisa M. O Hara, PharmD, CGP Corporate Director of Clinical Services The State Operations Manual Part 1: F329 Unnecessary Drugs Medication Management Defined Helps promote
More information1/23/2014 TOPICS PHARMACOLOGY: UPDATES AND REVIEW. Elizabeth Reeve MD HealthPartners Medical Group Gillette Children s Specialty Heath Care
PHARMACOLOGY: UPDATES AND REVIEW Elizabeth Reeve MD HealthPartners Medical Group Gillette Children s Specialty Heath Care TOPICS General pharmacology concepts when prescribing for children and adults When
More information--------------------------- RECENT MAJOR CHANGES -------------------------Warnings and Precautions:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (olanzapine and fluoxetine) capsules
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationOttiliavej 9 Tlf. +45 36 30 13 11 E-mail information@lundbeck.com DK-2500 Valby, Danmark Fax +45 36 43 82 62 www.lundbeck.com
H. Lundbeck A/S Ottiliavej 9 Tlf. +45 36 30 13 11 E-mail information@lundbeck.com DK-2500 Valby, Danmark Fax +45 36 43 82 62 www.lundbeck.com Press Release Valby, December 11, 2014 Otsuka and Lundbeck
More informationMedication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
More informationMedications for bipolar disorder
Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationGUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Version: 2
SH CP 29 GUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Summary: Guidelines for the use of paliperidone palmitate (Xeplion ) Keywords (minimum of 5): (To assist policy search engine) Target
More informationHow To Ensure That Children With Angegea Are Treated Properly
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL SECOND-GENERATION ANTIPSYCHOTIC DRUG USE AMONG MEDICAID-ENROLLED CHILDREN: QUALITY-OF-CARE CONCERNS Daniel R. Levinson Inspector General
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More informationMEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:
MEDGUIDE SECTION Medication Guide SEROQUEL (SER-oh-kwell) (quetiapine fumarate) Tablets Read this Medication Guide before you start taking SEROQUEL and each time you get a refill. There may be new information.
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More informationName: Date of Birth: Phone: ( ) Gender: Mailing Address:
To apply for help in affording your Sunovion prescription, please mail or fax a completed application to: Sunovion Support Prescription Assistance Program ( Program ) PO Box 220285, Charlotte, NC 28222-0285
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationA few general principles regarding medications are important to consider before initiating therapy in individuals diagnosed with a dementia
MEDICATIONS USED FOR THE MANAGEMENT OF DEMENTIA AND RELATED BEHAVIORIAL COMPLICATIONS* R.Ron Finley, B.S Pharm, R.Ph,CGP, Aimee Loucks, Pharm. D., Gil D. Rabinovici, M.D The following is intended to be
More informationABILIFY* PRODUCT MONOGRAPH. Aripiprazole Tablets. 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Antipsychotic agent
PRODUCT MONOGRAPH Pr ABILIFY* Aripiprazole Tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg Antipsychotic agent Bristol-Myers Squibb Canada Montreal, Canada Date of Preparation: 3 July 2009 Date of Revision:
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationGenome wide association study of extreme obesity defined by electronic medical record phenotyping
1 Genome wide association study of extreme obesity defined by electronic medical record phenotyping The pseudo code and flowchart for Geisinger extreme obesity cohort are below. Questions regarding this
More informationPARTNERSHIP HEALTHPLAN OF CALIFORNIA MEDI-CAL PROVIDER MANUAL CLAIMS DEPARTMENT
PARTNERSHIP HEALTHPLAN OF CALIFORNIA MEDI-CAL PROVIDER MANUAL CLAIMS DEPARTMENT X.J. Mental Health Services 1. For claims with dates of service on or before January 1, 2014: Mental Health Services are
More informationHow To Safely Use Aripiprazole
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bipolar I Disorder Reported prevalence rates for bipolar I disorder differ due to local variations in psychiatric practice, variations
More informationMajor Depressive Disorder:
Major Depressive Disorder: An Actuarial Commercial Claim Data Analysis July 2013 Prepared by: Milliman, Inc. NY Kate Fitch RN, MEd Kosuke Iwasaki FIAJ, MAAA, MBA This report was commissioned by Takeda
More informationImportant Safety Information about ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension
Important Safety Information about ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension Boxed Warnings Post-Injection Delirium/Sedation Syndrome Adverse events with signs and symptoms
More informationGUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
More informationWorkshop: Management of Depression in the Primary Care Setting, Kaiser Permanente of Ohio s Multidisciplinary Model
Workshop: Management of Depression in the Primary Care Setting, Kaiser Permanente of Ohio s Multidisciplinary Model Larissa Elgudin, MD, Chief of Behavioral Health Services Colleen O Malley RN, BSN, Regional
More informationDepression in the Elderly: Recognition, Diagnosis, and Treatment
Depression in the Elderly: Recognition, Diagnosis, and Treatment LOUIS A. CANCELLARO, PhD, MD, EFAC Psych Professor Emeritus and Interim Chair ETSU Department of Psychiatry & Behavioral Sciences Diagnosis
More informationBehavior and Developmental Disorders, Bipolar Disorder, and Schizophrenia Comparing safety and effectiveness
Use of Antipsychotic Medication in Children and Teens to Treat: Behavior and Developmental Disorders, Bipolar Disorder, and Schizophrenia Comparing safety and effectiveness Contents Our Recommendations.......................................
More informationMAJOR DEPRESSION DURING CONCEPTION AND PREGNANCY: A Guide for Patients and Families
MAJOR DEPRESSION DURING CONCEPTION AND PREGNANCY: A Guide for Patients and Families David A. Kahn, MD, Margaret L. Moline, PhD, Ruth W. Ross, MA, Lee S. Cohen, MD, and Lori L. Altshuler, MD www.womensmentalhealth.org
More information2. The prescribing clinician will register with the designated manufacturer.
Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased
More informationIMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:
Case Number: CM13-0018009 Date Assigned: 10/11/2013 Date of Injury: 06/11/2004 Decision Date: 01/13/2014 UR Denial Date: 08/16/2013 Priority: Standard Application Received: 08/29/2013 HOW THE IMR FINAL
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationPaxil/Paxil-CR (paroxetine)
Generic name: Paroxetine Available strengths: 10 mg, 20 mg, 30 mg, 40 mg tablets; 10 mg/5 ml oral suspension; 12.5 mg, 25 mg, 37.5 mg controlled-release tablets (Paxil-CR) Available in generic: Yes, except
More informationMEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS. Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D.
MEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D. Introduction Tourette Syndrome (TS) or Tourette s Disorder
More informationDepre r s e sio i n o i n i a dults Yousuf Al Farsi
Depression in adults Yousuf Al Farsi Objectives 1. Aetiology 2. Classification 3. Major depression 4. Screening 5. Differential diagnosis 6. Treatment approach 7. When to refer 8. Complication 9. Prognosis
More informationCorporate Presentation May 13, 2015
Corporate Presentation May 13, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and
More informationAntidepressant treatment in adults
Antidepressant treatment in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and
More informationDementa Formulary Guidance [v1.0]
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
More informationCLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
More informationXenazine (tetrabenazine) Treatment Form
Xenazine (tetrabenazine) Treatment Form Step 1: Patient Information Name: (First) (Middle) (Last) Sex: Male Female DOB: Address: City: State: Zip Code: Phone: Cell Phone: Best Time to Call: E-mail: Preferred
More informationTREATING BIPOLAR DISORDER
TREATING BIPOLAR DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition, originally published in April 2002. 1 For Continuing Medical
More informationCarol Childers Director Teva Neuroscience, Inc. 901 East 104 th Street, Suite 900 Kansas City, MO 64131. RE: ANDA 076809 Clozapine tablets USP MA# 44
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 Carol Childers Director Teva Neuroscience, Inc. 901 East 104 th Street, Suite 900 Kansas
More informationDisclosure Statement. Nursing Facility Regulations and Psychotropic Medication Use. Learning Objectives (Cont) Learning Objectives
Nursing Facility Regulations and Psychotropic Medication Use Jeffrey C. Reist PharmD, BCPS College of Pharmacy The University of Iowa December 2010 Disclosure Statement I, Jeffrey Reist, PharmD, BCPS do
More informationMOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic
More informationOlanzapine Odt. olanzapine kills. olanzapine rapids. olanzapine sleep. olanzapine treats what. olanzapine neuroleptic malignant syndrome
Olanzapine Odt olanzapine kills olanzapine rapids olanzapine sleep olanzapine treats what olanzapine neuroleptic malignant syndrome olanzapine nausea olanzapine eps olanzapine how supplied olanzapine formulations
More informationNorth of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
More informationjournal of medicine The new england Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia abstract
The new england journal of medicine established in 1812 september 22, 2005 vol. 353 no. 12 Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Jeffrey A. Lieberman, M.D., T. Scott
More informationTreatment of Behavioral Health Disorders in Adolescents: Depression, Bipolar Disorder, Schizophrenia
Treatment of Behavioral Health Disorders in Adolescents: Depression, Bipolar Disorder, Schizophrenia ELINORE F. MCCANCE-KATZ, MD, PHD CHIEF MEDICAL OFFICER SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION
More informationOlanzapine Fda Indications
Olanzapine Fda Indications olanzapine eps olanzapine dosing olanzapine toxicity olanzapine epocrates olanzapine benzo olanzapine abuse olanzapine interactions olanzapine names olanzapine zombie olanzapine
More informationSummary of the risk management plan (RMP) for Ionsys (fentanyl)
EMA/764409/2015 Summary of the risk management plan (RMP) for Ionsys (fentanyl) This is a summary of the risk management plan (RMP) for Ionsys, which details the measures to be taken in order to ensure
More informationOlanzapine Level olanzapine pronunciation olanzapine vomiting olanzapine toxicity
Olanzapine Level 1 olanzapine nursing implications 2 olanzapine benzo 3 olanzapine joint pain 4 olanzapine generic name 5 olanzapine insomnia 6 olanzapine usp 7 olanzapine ingredients 8 olanzapine nausea
More informationBipolar Disorder Practice Guidelines for Adults
Bipolar Disorder Practice Guidelines for Adults Introduction PerformCare s condensed guidelines for the treatment of Bipolar Disorder are derived from the American Psychiatric Association (APA) Guidelines
More informationOlanzapine Renal Dosing
Olanzapine Renal Dosing olanzapine uses olanzapine binge eating olanzapine fluoxetine olanzapine benzo olanzapine other names olanzapine generic availability olanzapine generic name olanzapine adverse
More informationOlanzapine Elderly Dementia
Olanzapine Elderly Dementia olanzapine journal articles olanzapine generic name olanzapine recreational olanzapine used for anorexia olanzapine usp olanzapine liquid olanzapine jubilant olanzapine how
More informationOlanzapine Uptodate olanzapine make you gain weight olanzapine structure olanzapine st john's wort
Olanzapine Uptodate olanzapine drug class olanzapine generic name olanzapine youtube olanzapine action olanzapine medscape olanzapine ingredients olanzapine make you gain weight olanzapine bluelight olanzapine
More informationRISPERDAL (risperidone)
RISPERDAL (risperidone) Highlights of Prescribing Information These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (risperidone)
More informationOlanzapine Dosage Forms
Olanzapine Dosage Forms olanzapine rash olanzapine history olanzapine ingredients olanzapine ketoacidosis olanzapine msds olanzapine narcotic olanzapine classification olanzapine geriatric olanzapine chemical
More informationOlanzapine Maximum Dose
Olanzapine Maximum Dose olanzapine breastfeeding olanzapine hyponatremia olanzapine blood sugar olanzapine class olanzapine long acting olanzapine for delirium olanzapine jubilant 10 mg olanzapine tab
More informationOlanzapine Uses. olanzapine generic name. olanzapine uptodate. olanzapine other names. olanzapine vomiting. olanzapine leukopenia.
Olanzapine Uses olanzapine generic name olanzapine uptodate olanzapine other names olanzapine vomiting olanzapine leukopenia olanzapine nami olanzapine high abuse olanzapine medication olanzapine grapefruit
More informationOlanzapine Generic Availability
Olanzapine Generic Availability olanzapine msds olanzapine kills olanzapine grapefruit juice olanzapine neuroleptic malignant syndrome olanzapine abuse olanzapine used for anxiety olanzapine off label
More informationOlanzapine Kidney Damage
Olanzapine Kidney Damage 1 olanzapine generic price 2 olanzapine ocd 3 olanzapine uk 4 olanzapine grapefruit juice 5 olanzapine contraindications 6 olanzapine manufacturer 7 olanzapine drug test 8 olanzapine
More informationolanzapine is it a narcotic olanzapine narcotic olanzapine how supplied olanzapine vomiting olanzapine jubilant 10 mg olanzapine teaching olanzapine
Olanzapine Kick In olanzapine nursing implications olanzapine mechanism of action olanzapine images olanzapine dosing olanzapine kick in olanzapine neuroleptic malignant syndrome olanzapine xerostomia
More information